Tools chosen: kalshi_direct kalshi_related claude_news claude_news gdelt_news wikipedia code_execution polymarket_related

Sub-questions (Fermi decomposition)

Planner reasoning

This is a Kalshi market on the 4-year average (2025–2028) of US measles cases being ≥5000, i.e. a cumulative total ≥20,000 across the Trump term. The key empirical inputs are the confirmed 2025 CDC count (a record ~2,300 for post-elimination era), the current 2026 pace, vaccination-rate trends/elimination-status risk, and how the market prices adjacent thresholds. I'll anchor on the Kalshi price ladder and then gather CDC case-count data and news on outbreak trajectory.

# Current state 2025 finished at a CDC-confirmed 2,289 cases (highest since 1991). 2026 is running well ahead of that pace — 2,777 confirmed cases as of Aug 21, 2026, with several months still to report — putting full-year 2026 plausibly in the 3,500-5,000+ range. The market resolves on the 2025-2028 four-year average, requiring a cumulative ~20,000 cases (~5,900/yr average for 2026-2028) to hit "at least 5000." # Timeline of key events - 2025-01 to 2025-08: West Texas/New Mexico measles outbreak (Mennonite community-centered), 3 deaths, declared over Aug 18, 2025 (confirmed, Wikipedia/CDC). - 2025 (full year): CDC confirms final tally of 2,289 cases, 48 outbreaks, 90% outbreak-associated, 3 deaths, highest since 1991 (confirmed, CDC). - 2025-06-20: Utah-Arizona border outbreak begins in under-vaccinated communities; grows to 680+ cases across 22/29 UT counties by mid-2026 (confirmed, CIDRAP). - 2025-2026 school year: Kindergarten MMR coverage falls to 92.4% (from 95.2% in 2019-20); exemptions rise to record 4.2% (~155,000 kids) (confirmed, CDC SchoolVaxView/KFF). - 2026-01-05: HHS/CDC announce cutting universally recommended childhood vaccines from 17 to 11; MMR proposed to be split into 3 separate shots (confirmed/reported, The Conversation, US News). - 2026-03: Federal judge rules Kennedy's ACIP revamp unlawful, invalidating downgrades to Hep B/COVID recommendations; CDC nonetheless renews ACIP through April 2028 (confirmed, US News). - 2026-03: PAHO announces it will formally review US measles elimination status in November 2026; Canada already lost its own elimination status Nov 2025 (confirmed, AAP/CIDRAP). - 2026 (through Aug): New outbreaks in South Carolina (670 cases, now over), Virginia (129, up from 5 in 2025), Pennsylvania (hundreds since July); 36 new outbreaks reported (confirmed, CDC/CIDRAP). - 2026-08-21: CDC updates 2026 YTD total to 2,777 confirmed cases, 94% outbreak-associated (confirmed, CDC). - Pending Nov 2026: PAHO elimination-status determination — CIDRAP analysis says loss is "highly likely" (reported/analyst opinion). # Event Will the average annual US measles case count over 2025-2028 (Trump term) be at least 5,000 (i.e., cumulative ≥20,000 cases)? # Outcomes to forecast - Yes (average ≥5,000/yr) - No (average <5,000/yr) # Kalshi market anchor KXAVGMEASLESDJT-29-5000 "Yes" currently priced at **32%** (7-day: -6pts, 30-day: +2pts; range 28-70% over 40 days of data; avg daily volume 315 contracts). Market has come down sharply from a much higher historical peak (70%) but ticked up slightly over the past month before the recent pullback. # Sub-question answers 1. **2025 CDC total / prior record**: 2,289 confirmed cases in 2025, highest since 1991 (CDC, AAP). No comparable "post-elimination record" year exceeded this since 2000 elimination. 2. **2026 YTD pace**: 2,777 confirmed as of Aug 21, 2026 — already exceeds all of 2025 with ~4 months remaining; likely full-year 2026 total in the 3,500-5,000+ range (CDC, CIDRAP, ABC News). 3. **Cumulative math**: Need 20,000 total over 4 years; with 2025 at ~2,289, remaining 2026-2028 must average ~5,900/yr — roughly 2.5-4x the 2025 baseline sustained for three straight years (code_execution analysis). 4. **Vaccination/elimination trends**: Kindergarten MMR coverage down to 92.4% (from 95.2% in 2019-20); exemptions at record 4.2% (~155,000 kids); >75% of states below 95% target. PAHO to review US elimination status Nov 2026; CIDRAP calls loss "highly likely" (CDC, KFF, CIDRAP). 5. **Other Kalshi thresholds**: Not directly retrieved (series returned 0 additional markets in this pull), so implied distribution across 1000/2000/3000 buckets is unknown — a gap. 6. **Structural policy risk**: RFK Jr./HHS cut universally-recommended childhood vaccines 17→11, proposed splitting MMR into 3 shots (Jan 2026); ACIP revamp partially blocked by courts (Mar 2026) but ACIP renewed through 2028, signaling continued disruption risk. Notably, RFK Jr. himself later urged parents to vaccinate for measles (2026), a partial reversal (news reports). # Key facts (high-confidence, factual) 1. [CDC] 2025 final: 2,289 cases, 48 outbreaks, 3 deaths, worst since 1991. 2. [CDC, Aug 21 2026] 2026 YTD: 2,777 cases, 94% outbreak-associated. 3. [CDC/KFF] Kindergarten MMR coverage 92.4% (2025-26 school year), exemptions record 4.2%. 4. [Wikipedia/CDC] 2025 Southwest outbreak (TX/NM) declared over Aug 18, 2025. 5. [CIDRAP/AAP] PAHO to review US elimination status Nov 2026; Canada already lost status Nov 2025. 6. [US News/Conversation] Jan 2026 HHS vaccine schedule overhaul; Mar 2026 court partially blocks ACIP changes. # Cross-market signals - Kalshi related: No additional KXAVGMEASLESDJT threshold markets retrieved in this pull (gap). - Polymarket: No matching markets found (0/100 scanned). - Sportsbook implied: N/A (not applicable to this event type). # Analyst opinions and speculation - CIDRAP: US elimination-status loss in 2026 "appears highly likely." - Johns Hopkins expert (US News): surge pace in July 2026 "particularly striking," with outbreaks still active in multiple states. - code_execution Monte Carlo: base-rate/blended estimate of P(Yes) ≈ 5-15% (centered ~10%), given historical tendency of US outbreaks to self-limit after 1-2 years; only sustained 2.5x+ annual growth for 3 years clears the 20,000-case bar. # Directional lean per outcome - **Yes (≥5,000 avg)**: Supported by 2026 already exceeding 2025 with months left, declining vaccination coverage/rising exemptions, policy disruption (schedule cuts, MMR-split proposal) that could further erode uptake, and impending elimination-status loss which may embolden hesitancy. Opposed by: quantitative math requiring ~2.5-4x sustained multi-year growth, historical pattern of outbreaks (2019, Southwest 2025) burning out within a year, and RFK Jr.'s recent pro-measles-vaccine messaging (partial reversal) which could dampen further erosion. - **No (<5,000 avg)**: Supported by base-rate outbreak dynamics (containment likely for at least some clusters, e.g., SC outbreak already over), the steep multiplier required, and model-based P(Yes) estimates (~10-15%) well below market's 32%. Opposed by accelerating 2026 trajectory and structural vaccine-policy risks that make continued deterioration plausible into 2027-2028. # Gaps / unknowns - No confirmed 2026 full-year total yet (still accumulating). - No visibility into pricing of adjacent Kalshi thresholds (1000/2000/3000) to back out implied full distribution. - Uncertain whether 2027-2028 will see new large-scale outbreaks or containment; no forward-looking outbreak forecasts in research. - PAHO Nov 2026 decision outcome not yet known; effect of elimination-status loss on case trajectory is speculative. # Calibration anchors - Kalshi current YES price: 32% (anchor), down from a 70% high, recent 7-day decline of 6pts. - Quantitative/Monte Carlo base-rate estimate: ~10% (range 5-15%), notably below market price — suggesting market may be pricing recency/momentum from 2026 surge more heavily than base-rate containment dynamics. - Precedent: pre-2025 US measles outbreaks (2014, 2019) peaked then declined within 12-18 months without reaching sustained 5,000+/yr rates.

1. Both forecasts converge almost identically (20% vs 22%) despite claiming independent reasoning, and neither explores why the Monte Carlo base rate (~10%) might itself be wrong — e.g., the model's "outbreaks self-limit in 1-2 years" reference class (2014, 2019) may not apply when multiple concurrent large outbreaks (Utah 680+, SC 670, Virginia 129, PA "hundreds") are running simultaneously across different states rather than as a single cluster, which is a structurally different (potentially more persistent) pattern than the historical base rate captures. 2. Neither forecast fully exploits the brief's own upper bound: 2026 is "plausibly in the 3,500-5,000+ range," and if 2026 lands at the top of that range (~5,000), the required 2027-2028 average drops meaningfully below the "6,500-7,000/year" figure both cite — they anchor on the midpoint/low end of 2026 projections rather than modeling the full distribution, understating upside tail risk. 3. Both treat the PAHO elimination-status loss (Nov 2026, called "highly likely" by CIDRAP) as a soft signal rather than a potential regime-change variable — historically, losing elimination status is associated with a shift from imported-outbreak dynamics to sustained endemic transmission, which could structurally invalidate the "outbreaks burn out in 12-18 months" precedent both rely on heavily. 4. Neither forecast addresses the brief's noted gap that adjacent Kalshi threshold markets (1000/2000/3000) were not retrieved, meaning they had no way to cross-check whether the market's implied full distribution is consistent with a 32% "≥5000" price — this is a missed calibration check both should have flagged as a limitation more explicitly. 5. Both forecasts justify landing "below market, above the base-rate model" but do so via similar hand-wavy averaging (20% and 22%) without a transparent weighting rationale (e.g., why not 15% or 25%) — this suggests anchoring on each other's likely output space rather than a principled blend of the 10% model and 32% market. 6. Neither considers that RFK Jr.'s partial reversal (urging measles vaccination) is only one countervailing policy signal, while the more consequential MMR-split proposal and 17→11 vaccine schedule cut remain largely unresolved for 2027-2028 — the forecasts undercount the scenario where policy disruption compounds over the remaining two years rather than plateauing, which is the main channel by which "Yes" could actually occur.

23% (61% confidence)

Yes: 23% No: 77%

The arithmetic bar is steep: with 2025 locked at 2,289 and 2026 likely landing near 3,500-5,000, 2027 and 2028 would each need roughly 6,000-7,000 cases — a further large jump on top of an already record year. Historical US dynamics (2014, 2019, the 2025 Southwest cluster, SC's already-ended 670-case outbreak) favor burnout, supporting 'No.' However, the critique is right that the reference class may not fit: multiple simultaneous multi-state outbreaks, kindergarten MMR at 92.4% with record 4.2% exemptions, unresolved MMR-split/schedule-cut policy risk, and a likely PAHO elimination-status loss in Nov 2026 could mark a regime shift toward sustained endemic transmission, and the upper end of 2026 projections would materially lower the 2027-28 requirement. I therefore nudge slightly above both forecasts and well above the ~10% base-rate model, while staying below the 32% market price (which has itself been trending down) because the required multiplier remains demanding.

Total pipeline time: 259.2s